Advanced neuroscience and digital therapeutics business MindMaze Healthcare has revealed its plans for ‘exponential growth’ through its commercial product portfolio and clinical pipeline.
The business is a key name in digital neurotheraputics solutions with its development of its game-based software products Rehab DTx, which supports neurorehabilitation, and Neuro DTx aimed at neurorestoration.
Its serious digital therapeutics (DTx), a combination of neuroscience and AI-powered, immersive game-based activities, are improving clinical outcomes for patients with neurological conditions including stroke, TBI, mild cognitive impairment, Alzheimer’s, Parkinson’s and MS.
Working with more than 10,000 patients in 20 countries worldwide, both in hospital and home settings, the Rehab DTx platform and its telerehabilitation service has supported patients around the world during the pandemic through its products’ remote offering. 
MindMaze, founded in 2012, has revealed it is working with leading academic institutions to develop a robust pipeline of clinical evidence and in the next few years expects to have at least three new prescription digital therapeutic solutions for chronic stroke, Parkinson’s, and mild cognitive impairment.
The company is now predicting significant growth in the years ahead through its continued innovation in digital neurotheraputics.
“At MindMaze, we are leading the delivery of digital neurotherapeutics with our groundbreaking solutions for some of the most challenging neurological conditions,” says Tej Tadi, founder and chief executive at MindMaze.
“We are differentiated in the burgeoning digital therapeutics industry. MindMaze has a global commercial footprint that is generating considerable revenue today and will drive explosive revenue growth in the next years.”
MindMaze’s products are in use in inpatient units in the United States, including Johns Hopkins University Hospital and Mt. Sinai Health Systems.
In addition to Rehab DTx and Neuro DTx solutions, MindMaze also offers smart peripherals and quantitative assessments that allow tracking of motor and cognitive capacities.
The data from these assessments is then analysed on an AI cloud-based platform and returned in a digestible form to patients and clinicians.
